Born out of the genomics bubble, deCode Genetics Inc. jumped 41% to $28 in its first day of trading on the NASDAQ in 2000, valuing the company at $1.1 billion. Since then, deCode (NASDAQ:DCGN) has fallen 99% and is valued at about $2 million. Along the way, the population genetics company signed discovery partnerships with big pharmas like Merck & Co. Inc. (NYSE:MRK) and Roche (SIX:ROG; OTCQX:RHHBY). But the biotech's attempts to reinvent itself as a drug developer after the genomics bubble burst failed to pan out. In 2008, CEO Kari Stefansson said deCode was "sharpening" its focus on its diagnostics business, a change in strategy that came too late, as the company filed for Chapter 11 in November. Selected events tracked against deCode's weekly